熱門資訊> 正文
Insulet因风险增加而在Oppenheimer降级
2026-08-06 02:52
- 奧本海默控股(OPY) 0
- 銀休特(PODD) 0
- 德康醫療(DXCM) 0
- Oppenheimer lowered Insulet (PODD) to perform from outperform, citing growing risks from a softer-than-expected growth outlook.
- The bank also removed its price target.
- The downgrade came as the insulin pump maker's Q2 double beat was overshadowed after lowering its full-year revenue outlook.
- Insulet believes type 2 diabetes "challenges are execution issues; we believe these are more structural in nature," analyst Suraj Kalia wrote.
- "Not only is patient retention an issue, but utilization will also remain a concern long term," he added.
More on Insulet
- Insulet Corporation (PODD) Q2 2026 Earnings Call Transcript
- Insulet Corporation 2026 Q2 - Results - Earnings Call Presentation
- Insulet Corporation: A High-Quality Growth Story Trading At A Reasonable PEG
- Insulet forecasts 2026 revenue growth of 20%-22% as it adjusts U.S. assumptions on type 2 retention
- Insulet sends Tandem, DexCom lower after guidance cut
推薦文章
港股周報 | 黃金股狂飆！靈寶黃金周升24%；段永平「被動減持」泡泡瑪特；藥明康德升近20%創新高
一周財經日曆 | 重磅財報周！騰訊、Lumentum、中芯國際輪番登場！美國7月CPI攜零售數據來襲
8月8日外盤頭條：伊朗內部辯論霍爾木茲協議措辭 非農爆冷削弱加息預期 SpaceX將自建發電廠保障電力供應
Palantir股價將創下自2024年以來最佳單周表現，該股已不再是AI領域的失意者
7月非農就業數據走弱，支持美聯儲維持利率不變，但加息選項並未徹底排除
美股前瞻 | 聚焦20：30！市場靜候7月非農數據；特朗普政府擬加碼佈局關鍵礦產；應用光電計劃大規模擴產，光通信盤前集體飆升
港股異動 | 創新葯概念再度走強，再鼎新葯勁升14%，Q2產品收入環比增長11%；藥明生物升逾5%，百濟神州升逾3%
港股異動 | AI硬件股多數上漲，建滔積層板、勝宏科技漲逾5%，兆易創新漲逾3%；南方兩倍做多海力士跌逾9%
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
